• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Upstream Bio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/12/25 4:18:05 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UPB alert in real time by email
    8-K
    0002022626false00020226262025-06-102025-06-10

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of report (date of earliest event reported): June 10, 2025

     

     

    UPSTREAM BIO, INC.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware

    001-42366

    38-4187694

    (State or other jurisdiction
    of incorporation)

    (Commission file number)

    (IRS employer
    identification no.)

     

     

     

     

     

    890 Winter Street

    Suite 200

     

    Waltham, Massachusetts

     

    02451

    (Address of principal executive offices)

     

    (Zip code)

     

    Registrant’s telephone number, including area code: (781) 208-2466

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.001 par value per share

     

    UPB

     

    The Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 5.07 Submission of Matters to a Vote of Security Holders.

    Upstream Bio, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) on June 10, 2025. As of April 14, 2025, the record date for the Annual Meeting, there were 53,688,703 shares of the Company’s common stock outstanding and entitled to vote at the Annual Meeting. The Company’s stockholders voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 17, 2025: (i) to elect each of Erez Chimovits, M.B.A., M.Sc. and Marcella Kuhlman Ruddy, M.D., M.S. as Class I directors of the Company, to serve until the Company’s 2028 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified, or until his or her earlier death, resignation or removal (“Proposal 1”), and (ii) to ratify the selection of PricewaterhouseCoopers LLP (“PwC”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 (“Proposal 2”).

    Proposal 1 - Election of Class I Director Nominees

    The Company’s stockholders approved the Class I director nominees recommended for election in Proposal 1 at the Annual Meeting. The results of Proposal 1 were as follows:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Class I Director Nominee

    For

    Withheld

    Broker
    Non-Votes

    Erez Chimovits, M.B.A., M.Sc.

    42,089,191

    241,430

    1,296,674

    Marcella Kuhlman Ruddy, M.D., M.S.

    41,993,308

    337,313

    1,296,674

    Proposal 2 - Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm

    The Company’s stockholders ratified the selection of PwC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The results of Proposal 2 were as follows:

     

     

     

     

     

     

     

     

     

     

    For

    Against

    Abstain

    43,600,758

    996

    25,541

    No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    Upstream Bio, Inc.

     

     

     

     

    Date:

    June 12, 2025

    By:

    /s/ E. Rand Sutherland

     

     

     

    E. Rand Sutherland, M.D.
    Chief Executive Officer

     


    Get the next $UPB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $UPB

    DatePrice TargetRatingAnalyst
    11/5/2024$75.00Overweight
    Piper Sandler
    11/5/2024$38.00Overweight
    JP Morgan
    11/5/2024Outperform
    William Blair
    11/5/2024Buy
    TD Cowen
    More analyst ratings

    $UPB
    SEC Filings

    See more
    • Upstream Bio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Upstream Bio, Inc. (0002022626) (Filer)

      6/12/25 4:18:05 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Upstream Bio Inc.

      10-Q - Upstream Bio, Inc. (0002022626) (Filer)

      5/6/25 7:10:23 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Upstream Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Upstream Bio, Inc. (0002022626) (Filer)

      5/6/25 7:05:10 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler initiated coverage on Upstream Bio with a new price target

      Piper Sandler initiated coverage of Upstream Bio with a rating of Overweight and set a new price target of $75.00

      11/5/24 6:29:20 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan initiated coverage on Upstream Bio with a new price target

      JP Morgan initiated coverage of Upstream Bio with a rating of Overweight and set a new price target of $38.00

      11/5/24 6:28:28 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • William Blair initiated coverage on Upstream Bio

      William Blair initiated coverage of Upstream Bio with a rating of Outperform

      11/5/24 6:28:02 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Renaud Ronald C Jr

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      6/12/25 4:17:33 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Ruddy Marcella K.

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      6/12/25 4:17:30 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Chimovits Erez

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      6/12/25 4:17:31 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Omega Funds Closes Oversubscribed $647 Million Fund VIII to Invest in Transformative Life Science Companies

      Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. Since its inception in 2004, Omega Funds has raised $2.5 billion to invest in exceptional entrepreneurs developing

      7/21/25 7:00:00 AM ET
      $BBNX
      $BCAX
      $KMTS
      $MORF
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

      – Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for verekitug into third indication, strengthening pipeline across severe respiratory diseases including chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and COPD – – Program updates also include completion of enrollment in Phase 2 clinical trial in severe asthma; top-line data now expected in first quarter of 2026 – WALTHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an in

      7/8/25 7:00:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

      – Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe mechanistic insights for greater potency with verekitug compared to tezepelumab – – Supports potentially differentiated profile of verekitug across a broad range of inflammatory diseases, including severe asthma, chronic obstructive pulmonary disease (COPD) and chronic rhinosinusitis with nasal polyps (CRSwNP) – WALTHAM, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the presentation of translationa

      6/15/25 7:45:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chimovits Erez bought $14,025,000 worth of shares (825,000 units at $17.00) and converted options into 3,609,789 shares (SEC Form 4)

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      10/17/24 4:19:30 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Orbimed Advisors Llc bought $14,025,000 worth of shares (825,000 units at $17.00) and converted options into 3,609,789 shares (SEC Form 4)

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      10/17/24 4:17:52 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Ai Upstream Llc bought $19,975,000 worth of shares (1,175,000 units at $17.00) and converted options into 4,319,410 shares (SEC Form 4)

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      10/17/24 4:05:04 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPB
    Leadership Updates

    Live Leadership Updates

    See more
    • Upstream Bio Appoints Stacy Price as Chief Technology Officer

      WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy Price, MS, PMP, as Chief Technology Officer. Ms. Price brings over 25 years of experience in technical operations, manufacturing, and product development in the biotechnology industry, across a variety of drug modalities. In this role, Ms. Price will oversee the expansion of technical operations and product development in support of Upstream Bio's global development of verekitug, with a focus on chemistry, manufacturing, and controls (CMC) pr

      5/20/25 7:00:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Upstream Bio Appoints Allison Ambrose as General Counsel

      WALTHAM, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the Company has appointed Allison Ambrose, J.D. as General Counsel. Ms. Ambrose is a senior legal leader with more than 15 years of experience providing counsel on a wide range of matters including corporate governance, securities law and compliance, and capital markets and corporate development transactions. Ms. Ambrose will oversee all aspects of Upstream's legal function and join the Company's executive leadership team. "I am thrilled to welcome Allison to

      12/17/24 8:00:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Upstream Bio Inc.

      SC 13G - Upstream Bio, Inc. (0002022626) (Subject)

      11/7/24 9:24:55 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Upstream Bio Inc.

      SC 13D - Upstream Bio, Inc. (0002022626) (Subject)

      10/22/24 4:06:27 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Upstream Bio Inc.

      SC 13G - Upstream Bio, Inc. (0002022626) (Subject)

      10/18/24 6:10:56 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care